Sugi Predict

Sugi Predict / Compounds / SCHEMBL526394

SCHEMBL526394

SCHEMBL526394

O=C(O)C(Br)N1C(=O)CCC1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.43
▸ PKM P14618 1/20 0.43
▸ SLC1A2 P43004 2/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ KMT2A Q03164 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ MME P08473 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ RECQL P46063 1/20 0.35
▸ CHRM2 P08172 1/20 0.34
▸ CHRM4 P08173 1/20 0.34
▸ CHRM5 P08912 1/20 0.34
▸ CHRM1 P11229 1/20 0.34
▸ CHRM3 P20309 1/20 0.34
▸ CYP2C19 P33261 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ CA12 O43570 1/20 0.32
▸ CA1 P00915 1/20 0.32
▸ CA9 Q16790 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6676631 0.77 CYP2C19 (0.42) ALDH1A1PKMSLC1A2KMT2AMEN1
SCHEMBL1564214 0.76 KMT2A (0.53) ALDH1A1PKMSLC1A2KMT2AMEN1
SCHEMBL57078 0.76 KMT2A (0.53) ALDH1A1PKMSLC1A2KMT2AMEN1
SCHEMBL23716973 0.75 ALDH1A1 (0.46) ALDH1A1PKMSLC1A2KMT2AMEN1
SCHEMBL31259418 0.75 ALDH1A1 (0.46) ALDH1A1PKMSLC1A2KMT2AMEN1
SCHEMBL432176 0.73 ALDH1A1 (0.44) ALDH1A1PKMSLC1A2KMT2AMEN1
SCHEMBL542300 0.73 RAB9A (0.41) ALDH1A1PKMSLC1A2KMT2AMEN1
SCHEMBL1906466 0.73 MEN1 (0.34) ALDH1A1PKMSLC1A2KMT2AMEN1
SCHEMBL15623779 0.73 RAB9A (0.41) ALDH1A1PKMSLC1A2KMT2AMEN1
SCHEMBL15623808 0.73 ALDH1A1 (0.53) ALDH1A1PKMSLC1A2SMN1; SMN2MME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2804631-B1 SURROBODY CONJUGATES I2 PHARMACEUTICALS INC (US) 2021-03-17 — — EP claimed
EP-2437790-B1 CONJUGATION METHODS IMMUNOGEN INC (US) 2019-02-20 — — EP claimed
EP-2675480-B1 METHODS OF PREPARATION OF CONJUGATES IMMUNOGEN INC (US) 2018-12-26 — — EP claimed
US-9056914-B2 Anticancer derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2015-06-16 — — US claimed
EP-2399609-B1 Process for preparing maytansinoid antibody conjugates IMMUNOGEN INC (US) 2015-03-18 — — EP claimed
EP-2478049-B1 A POLYMER SUPPORT UNIV CAPE TOWN (ZA) 2015-02-25 — — EP claimed
US-8952147-B2 Conjugates, preparation thereof, and therapeutic use thereof SANOFI (FR) 2015-02-10 — — US claimed
EP-2598507-A1 ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-06-05 — — EP claimed
CN-103140491-A Anticancer derivatives, preparation thereof and therapeutic use thereof SANOFI SA 2013-06-05 — — CN claimed
US-20130137659-A1 ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-30 — — US claimed
US-20120225089-A1 NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-09-06 — — US claimed
EP-2032172-B1 LEPTOMYCIN DERIVATIVES SANOFI SA (FR) 2012-06-06 — — EP claimed
WO-2012014147-A1 ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-02-02 — — WO claimed
EP-1813614-B1 Cytotoxic agents comprising new tomaymycin derivatives SANOFI SA (FR) 2011-10-05 — — EP claimed
US-6361777-B1 COVALENTLY COUPLING POLYSACCHARIDE TO BIOPOLYMER HAVING HYDROXYL, AMINO AND/OR MERCAPTO GROUPS BY ACTIVATING POLYSACCHARIDE WITH CYANOGEN BROMIDE, THIOLATING WITH AMINOTHIOL LINKER, REACTING WITH BIOPOLYMER DE STAAT DER NEDERLANDEN,VERTEGENWOORDIGD DOOR DE MINISTER VAN WELZIJN, VOLKSGEZONDHEID EN CULTUUR (NL) 2002-03-26 — — US claimed
EP-0396116-B1 Covalent attachment of specific binding members to a solid phase ABBOTT LAB (US) 1997-02-05 — — EP claimed
EP-0680512-A1 IMMUNOGENIC MENINGOCOCCAL LPS AND OUTER MEMBRANE VESICLES AND VACCINE THEREFROM STAAT DER NEDERLANDEN VERTEGENWOORDIGD DOOR DE MINISTER VAN WELZIJN, VOLKSGEZONDHEID EN CULTUUR (NL) 1995-11-08 — — EP claimed
WO-1994008021-A1 IMMUNOGENIC MENINGOCOCCAL LPS AND OUTER MEMBRANE VESICLES AND VACCINE THEREFROM DE STAAT DER NEDERLANDEN, VERTEGENWOORDIGD DOOR DE MINISTER VAN WELZIJN, VOLKSGEZONDHEID EN CULTUUR (NL) 1994-04-14 — — WO claimed
EP-4662205-A1 DERIVATIVES, IMMUNOGENS, AND ANTIBODIES AND USE OF THE SAME IN DETECTION OF ECSTASY-CLASS COMPOUNDS Siemens Healthcare Diagnostics, Inc. (US) 2025-12-17 — — EP disclosed
EP-0309863-A2 Composition and method to release an immune reaction to GnRH and method for the immunosterilization of mammals MOBAY CORPORATION (US) 1989-04-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225089-A1 NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF ERG28, CARS1, FOLH1 ALDH1A1 1912/4885PKM 3676/4885SLC1A2 2887/4885
US-20130137659-A1 ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF MCL1, TP53, MYC ALDH1A1 339/4885PKM 915/4885SLC1A2 4602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.